Our team has years of neurology drug discovery and development experience in the pharmaceutical and biotechnology arenas and is supported by world-class scientific founders and advisors.
Chief Executive Officer
Rita brings 30 years of experience in neuroscience research, drug discovery and development from senior leadership roles in biopharma and a distinguished academic research career.
Prior to joining Muna, she led small molecule, biologics and gene therapy programs in neurologic, neurodegenerative and rare genetic diseases at Sanofi, and psychiatry and pain programs at Pfizer.
Chief Operating Officer
Anders brings 25 years of experience in biotech leadership and venture capital investment.
Prior to joining Muna, he co-founded and was CEO of Orphazyme, creating an ambitious and mature clinical stage pipeline in rare protein misfolding and lysosomal storage diseases.
Jakob Busch-Petersen, PhD
Chief Development Officer
Jakob brings 25 years of experience in small molecule medicinal chemistry, drug discovery and technology in biopharma.
Prior to joining Muna, he was the head of small molecule external innovation at Roche responsible for scouting, and developing novel early stage therapeutic and technology programs with external partners.
Our Scientific Founders
Bart De Strooper, MD, PhD
Bart is an internationally renowned physician scientist at Katholieke Universiteit Leuven and the Vlaams Instituut voor Biotechnologie in Belgium and the Director of the United Kingdom Dementia Research Institute at University College London.
Bart and his team have made groundbreaking contributions to understanding and treating Alzheimer’s disease for over three decades.
Simon Glerup, PhD
Simon is a world-class scientist at Aarhus University in Denmark who has made significant contributions to the understanding of progranulin signaling pathways in the brain in health and disease.
Simon and his team’s insights into how the structure and function of key signaling molecules in these pathways are related has led to innovative approaches to developing small molecule therapeutics for Frontotemporal Dementia and neurodegenerative diseases.